RESUMO
Each year, new drugs are introduced to the market, representing structures that have affinity for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and serve as potential leads for the design of future medicines. This annual review is part of a continuing series highlighting the most likely process-scale synthetic approaches to 35 NCEs that were first approved anywhere in the world during 2021.
Assuntos
Desenho de Fármacos , Humanos , Preparações Farmacêuticas , Imunoconjugados/químicaRESUMO
New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.
Assuntos
Desenho de Fármacos , Imunoconjugados , HumanosRESUMO
New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.
Assuntos
Técnicas de Química Sintética/métodos , Compostos Orgânicos/síntese química , Preparações Farmacêuticas/síntese química , Animais , HumanosRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 39 new chemical entities approved for the first time globally in 2018.
Assuntos
Aprovação de Drogas , Preparações Farmacêuticas/química , Descoberta de Drogas , História do Século XXI , Estrutura MolecularRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 31 new chemical entities approved for the first time globally in 2017.
Assuntos
Aprovação de Drogas , Desenho de Fármacos , Modelos Químicos , Preparações Farmacêuticas/síntese química , Anti-Infecciosos/síntese química , Anti-Infecciosos/química , Antineoplásicos/síntese química , Antineoplásicos/química , Fármacos Gastrointestinais/síntese química , Fármacos Gastrointestinais/química , Fármacos Hematológicos/síntese química , Fármacos Hematológicos/química , Estrutura Molecular , Soluções Oftálmicas/síntese química , Soluções Oftálmicas/química , Preparações Farmacêuticas/química , Preparações Farmacêuticas/classificaçãoRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 19 new chemical entities that were approved for the first time in 2016.
Assuntos
Aprovação de Drogas/história , Preparações Farmacêuticas/história , Desenho de Fármacos , História do Século XXI , Estrutura Molecular , Preparações Farmacêuticas/síntese química , Preparações Farmacêuticas/químicaRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.
Assuntos
Descoberta de Drogas/métodos , Preparações Farmacêuticas/síntese química , Anti-Infecciosos/síntese química , Anti-Inflamatórios não Esteroides/síntese química , Antineoplásicos/síntese química , Fármacos Cardiovasculares/síntese química , Fármacos do Sistema Nervoso Central/síntese química , Técnicas de Química Sintética , Fármacos Gastrointestinais/síntese química , Hipoglicemiantes/síntese química , Receptores de Trombopoetina/agonistasRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.
Assuntos
Desenho de Fármacos , Comércio , Indústria FarmacêuticaRESUMO
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.
Assuntos
Preparações Farmacêuticas/síntese química , Desenho de Fármacos , Estrutura Molecular , Preparações Farmacêuticas/químicaRESUMO
New drugs introduced to the market every year represent a privileged structure for a particular biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two additional drugs which were launched at the end of 2011.
Assuntos
Preparações Farmacêuticas/síntese química , Estrutura Molecular , Preparações Farmacêuticas/químicaRESUMO
New drugs are introduced to the market every year and each represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 26 NCEs that were launched in the world in 2011.
Assuntos
Aprovação de Drogas , Desenho de Fármacos , Preparações Farmacêuticas/síntese química , HumanosRESUMO
New drugs are introduced to the market every year and each represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.
